$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Colitis - Pipeline Review, H2 2017

Colitis - Pipeline Review, H2 2017
[Lowest Price Guaranteed: $1,700]

Published by Global Markets Direct: 11 Jul 2017 | 105843 | In Stock
Related Topics: Gas , Healthcare

Introduction

Colitis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2017, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 2, 19 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Colitis - Pipeline Review, H2 2017

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Colitis - Overview

    Colitis - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Colitis - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Colitis - Companies Involved in Therapeutics Development

    Akebia Therapeutics Inc

    Alpha Cancer Technologies Inc

    Apollo Endosurgery Inc

    Bristol-Myers Squibb Company

    Concenter BioPharma Silkim Ltd

    Cosmo Pharmaceuticals NV

    Dr. Falk Pharma GmbH

    EA Pharma Co Ltd

    Genfit SA

    Immuron Ltd

    Ogeda SA

    Pfizer Inc

    RDD Pharma Ltd

    Saniona AB

    Sigmoid Pharma Ltd

    Synovo GmbH

    Thetis Pharmaceuticals LLC

    Colitis - Drug Profiles

    ACT-101 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AcTMP-1 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AKB-6899 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AN-346 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Antibody for Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    APY-0201 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BC-1215 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BMS-986104 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    budesonide - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CSA-13 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CSY-0073 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    dimethyloxalylglycine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    elafibranor - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ESN-601 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Gene Therapy to Activate PD-L1 for Colitis and Graft Versus Host Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GFC-101 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    IMM-124E - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibodies to Inhibit LTC4 for Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NK-007 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    PF-06425090 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RDD-2007 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    rifamycin CR - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RP-182 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule for Colitis and Arthritis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules for Crohn's Disease and Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TP-317 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TPC-1022 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target IL12 and IL23 for Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target IL23 for Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VE-303 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Colitis - Dormant Projects

    Colitis - Discontinued Products

    Colitis - Product Development Milestones

    Featured News & Press Releases

    Apr 18, 2017: Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies

    Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

105843 | GMDHC9523IDB

Number of Pages

94

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Crohn's & Colitis Foundation of America - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryCrohn's & Colitis Foundation of America (CCFA) is a healthcare foundation which offers treatm...
25 Nov 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Crohn's & Colitis Foundation of America - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryCrohn's & Colitis Foundation of America (CCFA) is a healthcare foundation that offers treatme...
27 Apr 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Colitis Global Clinical Trials Review, H1, 2016
Colitis Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Colitis G...
11 Mar 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Crohn's & Colitis Foundation of America - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryCrohn's & Colitis Foundation of America (CCFA) is a healthcare foundation that offers treatme...
09 Mar 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Colitis - Pipeline Review, H2 2017 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...